Skip to main content
Premium Trial:

Request an Annual Quote

WITA to Provide Proteomics Service to Food Giant Nestle

NEW YORK, Nov. 29 - WITA Proteomics of Berlin said Thursday that it would provide proteomic services to Swiss food giant Nestle.

Under the terms of the agreement, WITA Proteomics said it would use its High Performance Proteomics platform to identify proteins in food products. 

WITA Proteomics will retain certain rights to use the proteins it identifies for future diagnostic and therapeutic use whereas Nestle will keep all rights for food applications and certain rights for therapeutic and cosmetic applications.

The companies did not disclose the financial terms of the deal. 

The companies said that proteomics could help to determine whether post-translational modifications produce proteins of differing nutritional value. 

"The use of proteomics offers Nestlé a new tool for the continued development and manufacture of high quality value added food products,” Andrea Pfeifer, head of Nestle’s research center, said in a statement. 

One year ago, Nestle penned a deal with Lion Bioscience for its bioinformatics tools and platform.
The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.